Table 2.

Summary of performance of multiplexed markers on Bio-Rad and Millipore

Bio-Rad markers with acceptable performanceaBio-Rad markers with <25% detectabilitybMillipore markers with acceptable performanceMillipore markers with acceptable performanceaMillipore markers with <25% detectabilityb
A2MB_NGFAmylin_TotalMIP_1DEotaxin 3
CRPGM_CSFBCA_1PPGhrelin
CTACKIFNA2CCL19_MIP3BPYYIL_20
C PeptideIL_12P40CCL20_MIP3ASAAIL_21
EotaxinIL_15CKINESAPIL_28a
FerritinIL_1ACRPSCD30IL_3
FGF_BasicIL_2CTACKSCD40LIL_4
FibrinogenIL_3CXCL11_I_TACSCFIL_5
GhrelinLIFCXCL6_GCP2SDF_1AM_CSF
GIPMCP_3CXCL9_MIGSEGFRXCL1_Lympho
GLP_1TNFBC_PeptideSGP130Millipore markers
GlucagonEGFSILRIIwith >20% CVc
GROBio-Rad markersENA_78SIL_1RI
Haptoglobinwith >20% CVcEotaxinSIL_2RAGM_CSF
HGFEotaxin_2SIL_4RIL_10
IFNGB_NGFFGF_BasicSIL_6RIL_12P70
IL_16GM_CSFFIT_3_LigandSRAGEIL_13
IL_18G_CSFFractalkineSTNFRIIL_15
IL 1RAIL_10GIPSTNFRIIIL_17
IL 2RAIL_12P70GLP_1SVEGFR1IL_1B
IL_6IL_13GlucagonSVEGFR2IL_1RA
IL_8IL_15GROSVEGFR3IL_2
IL 9IL_17G_CSFTARCIL_21
InsulinIL_1AIFNA2TNF-αIL_23
IP_10IL 1BIFNGTPOIL_28A
LeptinIL_2IL_11TRAILIL_3
MCP_1MCIL_4IL_12P40TSLPIL_4
MIFIL_5IL_16VEGFIL_5
MIGIL_7IL_1AIL_6
MIP_1BLIFIL_29_IFNG1IL_7
M_CSFMCP_3IL_33IL_9
PAI_1MIP 1AIL_8I_309
PCTTNF_BINSULINM_CSF
PDGF_BBTPAIP_10TGFA
RantesLEPTINTNF-B
ResistinLIFXCL1_Lympho
SAAMCP_1
SAPMCP_2
SCFMCP_3
SCGF_BMCP_4
SDF_1AMDC
TNF-αMIP_1A
TRAILMIP_1B
VEGF
Visfatin
  • aAcceptable performance was defined as (i) being detectable in greater than 25% of the 100 samples on all 3 specimen types and (ii) across-batch CVs of less than 20% for blinded duplicates on at least 2 of the 3 specimen types.

  • bMarkers with less than 25% detectability on at least 1 of 3 (serum, heparin plasma, and EDTA plasma) specimen types.

  • cMarkers with CVs for across-batch duplicates greater than 20% on 2 or more of 3 specimen types. CVs were calculated for 20 blinded duplicate samples for each specimen type that were placed across different batches.